tiprankstipranks
Advertisement
Advertisement

AVIR Stock Latest News

Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call
Company AnnouncementsAtea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call
18d ago
AVIR
Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI
PremiumThe Fly
Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI
3M ago
AVIR
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026
PremiumCompany Announcements
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026
3M ago
AVIR
Is AVIR a Buy, Before Earnings?
PremiumPre-Earnings
Is AVIR a Buy, Before Earnings?
3M ago
AVIR
Atea Pharmaceuticals presents preclinical results of AT-587
PremiumThe Fly
Atea Pharmaceuticals presents preclinical results of AT-587
3M ago
AVIR
Atea Pharmaceuticals to highlight strategic priorities for FY26
PremiumThe FlyAtea Pharmaceuticals to highlight strategic priorities for FY26
5M ago
AVIR
Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial
Premium
The Fly
Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial
5M ago
AVIR
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism
Premium
Company Announcements
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism
7M ago
AVIR
Atea Pharmaceuticals Advances Antiviral Programs with New Data
PremiumCompany Announcements
Atea Pharmaceuticals Advances Antiviral Programs with New Data
7M ago
AVIR
AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
7M ago
AVIR
Atea Pharmaceuticals announces presentation of data on BEM, RZR
PremiumThe Fly
Atea Pharmaceuticals announces presentation of data on BEM, RZR
7M ago
AVIR
Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?
PremiumCompany Announcements
Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?
7M ago
AVIR
Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir
PremiumCompany AnnouncementsAtea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir
7M ago
AVIR
Atea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors
Premium
Company Announcements
Atea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors
7M ago
AVIR
Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination
Premium
The Fly
Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination
8M ago
AVIR
Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress
PremiumCompany Announcements
Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress
10M ago
AVIR
Atea Pharmaceuticals Advances in HCV Treatment Development
PremiumCompany Announcements
Atea Pharmaceuticals Advances in HCV Treatment Development
10M ago
AVIR
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
PremiumThe Fly
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
11M ago
AVIR
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting
12M ago
8K
AVIR
Atea Pharmaceuticals Advances HCV Treatment Trials
PremiumCompany AnnouncementsAtea Pharmaceuticals Advances HCV Treatment Trials
1y ago
AVIR
AVIR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
AVIR Upcoming Earnings Report: What to Expect?
1y ago
AVIR
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
Premium
The Fly
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
1y ago
AVIR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >